

Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)

Company name: NICHIBAN CO., LTD.

Listing: Tokyo Stock Exchange

Securities code: 4218

Consolidated Financial Results FY 3/2026 2Q



		FY 3/2026 Results 2Q	FY 3/2025 Results 2Q	YoY	FY 3/2026 Forecast 2Q	vs. Forecast
Net sales	Millions of yen	24,150	23,759	+1.6%	25,400	-4.9%
Gross profit	Millions of yen	7,214	7,243	-0.4%	_	_
SG&A	Millions of yen	6,188	6,069	+2.0%	_	_
Operating profit	Millions of yen	1,025	1,174	-12.6%	1,300	-21.2%
Operating profit margin	%	4.2	4.9	-0.7pt	_	_
Ordinary profit	Millions of yen	1,051	1,227	-14.3%	1,400	-24.9%
Profit attributable to owners of parent	Millions of yen	656	809	-19.0%	900	-27.1%

Consolidated Financial Results FY 3/2026 2Q



		10	1Q 2Q		3Q		4Q		
		Results	YoY	Results	YoY	Results	YoY	Results	YoY
Net sales	Millions of yen	11,923	+3.5%	12,226	-0.1%	_	_	_	_
Gross profit	Millions of yen	3,651	+4.3%	3,562	-4.8%	_	_	_	_
SG&A	Millions of yen	2,999	+0.4%	3,188	+3.4%	_	_	_	_
Operating profit	Millions of yen	651	+26.8%	374	-43.3%	_	_	_	_
Operating profit margin	%	5.5	+1.0pt	3.1	-2.3pt	_	_	_	_
Ordinary profit	Millions of yen	676	+15.2%	375	-41.3%	_	_	_	_
Profit attributable to owners of parent	Millions of yen	393	+17.8%	263	-44.7%	-	_	-	_


Consolidated Financial Results FY 3/2026 2Q



		FY 3/2022 Results	FY 3/2023 Results	FY 3/2024 Results	FY 3/2025 Results	FY 3/2026 Results 2Q	FY 3/2026 Forecast
Capital expenditures	Millions of yen	3,981	4,092	1,803	1,043	971	3,618
Depreciation	Millions of yen	2,545	2,757	2,792	3,145	1,413	2,869
R&D expenses	Millions of yen	1,057	1,110	1,202	1,345	688	1,478

Analysis of Operating Profit





Net sales



Domestic: Healthcare Products

7,280 Millions of yen (-0.5%)

(YOY)

- CARELEAVES_{TM} (+1%)
- ROIHI series (-1%)
- BATTLEWIN series (+2%)

Domestic: Stationery Products

2,216 Millions of yen (-1.2%)

(YOY)

- Cellulose tape (±0%)
- NICETACK_{TM} (-2%)

Domestic: EC

2,622 Millions of yen (+5.4%)

(YOY)

- Cellulose tape (+6%)
- NICETACK_{TM} (+4%)
- CARELEAVES_{TM} (+18%)

Domestic: Hospital Products

2,863 Millions of yen (+1.1%)

(YOY)

- Surgical tape (-1%)
- Hemostatic bandage (+1%)
- Wound care dressing (+1%)

Domestic: Industrial Products

6,576 Millions of yen (+2.6%)

(YOY)

- Packaging tape (+1%)
- Masking tape (+2%)
- Tabanera_{TM} tape (+10%)

Global

2,590 Millions of yen (+5.0%)

(YOY)

- ROIHI-TSUBOKO_{TM} COIN PLASTER Launched in South Korea
- CARELEAVES_{TM} (-3%)
- Panfix_{TM} Cellulose tape (-2%)
- Masking tape (-17%)
- PVC Masking tape (+33%)

■ Medium-term Management Plan "CREATION 2026" ♦ NICHIBAN



	CREATION 2026							
	FY 3/2025 Plan	FY 3/2025 Results	FY 3/2026 Plan	FY 3/2026 Forecast	FY 3/2027 Plan			
Net sales (100 millions of yen)	486	494	500	515	530			
Operating Profit (100 millions of yen)	24	25	32	30	45			
Ordinary Profit (100 millions of yen)	25	26	33	31	46			
Profit attributable to owners of parent (100 millions of yen)	19	19	25	20	35			
ROE	_	4.6%	—	—	8% or more			
Global sales ratio	_	10.5%	_	_	15%			
New products ratio	_	10.7%	 .	_	15%			

"CREATION 2026" Priority Themes





Restructuring of the Business Portfolio

- (1) Fundamental Improvement in Profitability in the **Tape Business Segment**
- (2) Allocation of Management Resources to Growth **Businesses and New Business Fields**





Globalization

- (1) Pursue Growth of the Three Sales Bases
- (2) Expand Functions to Achieve a 30% Global Sales Ratio in FY2030
- (3) Promote Globalization Across the Entire Group



Human Capital Management

- (1) Promote Diversity, Equity & Inclusion (DE&I)
- (2) Develop Autonomous Human Resources Capable of **Self-Transformation and Growth**
- (3) Improve Employee Health and Engagement
- (4) Introduce a New Human Resources System



Sticking to your needs

NICHIBAN Corporate Information

https://www.nichiban.com/corp/



Integrated Report 2025

https://www.nichiban.com/corp/sustainability/report/



This document contains the Company's current plans and earnings forecasts. These plans and projections are based on information currently available and are subject to change. Actual results may differ from these plans due to various conditions and factors in the future, and this document does not guarantee the realization of the plan. This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.